Panadiplon

Panadiplon is a drug that was under development for the treatment of anxiety and insomnia. It is a nonbenzodiazepine GABA_A receptor partial agonist of the imidazopyridine family. However, its development was discontinued due to liver toxicity issues in some patients.

Pharmacology

Panadiplon acts as a GABA_A receptor partial agonist. This means it enhances the effect of the neurotransmitter GABA on the GABA_A receptor, leading to sedative and anxiolytic effects. It is part of the imidazopyridine family, which also includes drugs like Zolpidem and Alpidem.

Development and Clinical Trials

Panadiplon was developed by the pharmaceutical company Wyeth. It underwent Phase II and III clinical trials for the treatment of anxiety and insomnia. However, the development was discontinued after some patients showed signs of liver toxicity.

Side Effects

The most common side effects of Panadiplon include drowsiness, dizziness, and headache. However, the drug was discontinued due to the risk of liver toxicity, which can lead to serious health problems such as liver failure.

See Also

• Nonbenzodiazepine
• GABA_A receptor
• Zolpidem
• Alpidem
• Wyeth

Panadiplon Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski